UNSPSC 51102824: Benzalkonium chloride/chloroxylenol/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.

UNSPSC 51102824 Benzalkonium chloride/chloroxylenol/hydrocortisone (Commodity) does not reflect the scope of work actually being solicited under this code in state and local procurement. The recent opportunities tagged to this Commodity code involve procurement of naloxone, antimicrobial/antifungal products, and safe drug deactivation systems — pharmaceutical products and medical supplies purchased by state health departments and county public health agencies to support emergency response and community health initiatives. The code's nominal scope (a specific topical compound used in skin-care and first-aid applications) does not align with what is being bought. State and local purchasers are acquiring finished pharmaceutical products and medical devices in bulk quantities, often through piggyback arrangements or competitive bidding processes tied to public health emergencies, overdose prevention programs, and epidemic preparedness, rather than the narrower chemical formulation the code nominally describes.

The recent activity appears concentrated in Florida and Illinois. Seminole County, Florida issued an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford with a two-year initial term and one-year renewal option; the Illinois Department of Public Health completed an award in August 2026 to Chartwell Rx LLC for $2,999,999.11 over the contract life (including renewals) for pharmaceutical warehouse supply through the MMCAP Infuse cooperative purchasing vehicle, though that particular award involved antibiotic tablets rather than the code's stated compound. Misalignment between the code and actual procurements suggests this Commodity code has limited relevance for firms positioned in this product family — acquisition patterns favor broader pharmaceutical sourcing codes or state-level cooperative purchasing frameworks rather than this narrow chemical designation.